{
    "nctId": "NCT00634634",
    "briefTitle": "Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer",
    "officialTitle": "Phase I/II Trial of Letrozole (Femara) and Sorafenib (Nexavar) in Postmenopausal Women With Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 52,
    "primaryOutcomeMeasure": "Sorafenib in Combination With Fixed Dose of of 2.5mg of Letrozole Maximum Tolerated Dose (MTD)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Histologically confirmed invasive breast cancer\n2. Stage IIIB, IIIC with T4 lesion or Stage IV disease\n3. Breast cancer must be ER-positive and/or PR-positive\n4. Age \u00b3 18 years of age\n5. ECOG performance status 0, 1 or 2\n6. Able to swallow and oral medication\n7. Adequate end organ function\n8. Written informed consent\n\nExclusion Criteria:\n\n1. Prior hormonal therapy for metastatic disease\n2. Prior chemotherapy for metastatic disease\n3. Prior treatment with sorafenib\n4. Brain metastases or leptomeningeal disease\n5. Evidence or history of bleeding\n6. Thrombolic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}